TYK MEDICINES-B (02410) announced that the Company's investigational Class 1 new drug, Mesylate Edotinib Tablets (TY-9591 tablets), has been proposed by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for inclusion in the priority review品种 list. The intended indication is for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, and are accompanied by central nervous system (CNS) metastases. The Board has also noted the recent unusual fluctuations in the Company's share price and trading volume. After making reasonable inquiries, the Board confirms that, as of the date of this announcement and aside from the information disclosed above, it is not aware of any reasons for such fluctuations, or any information that must be disclosed to avoid a false market in the Company's securities, or any inside information that must be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). As of the date of this announcement, the Board confirms that the Group's business operations are normal and stable, its core business is progressing smoothly, and there are no material matters requiring disclosure that have drawn the attention of the Board and the Company's management.